Horizon Pharma to pay $800M for rare disease drug developer

Horizon Pharma will spend about $800 million to buy Raptor Pharmaceutical and expand its portfolio of rare disease treatments, a growing area of focus for drugmakers. The Ireland-based drug developer said Monday that the deal will strengthen its business in the United States and provide a...

Horizon Pharma will spend about $800 million to buy Raptor Pharmaceutical and expand its portfolio of rare disease treatments, a growing area of focus for drugmakers.

The Ireland-based drug developer said Monday that the deal will strengthen its business in the United States and provide a platform to expand in Europe and other international markets.

Raptor's portfolio includes Procysbi, which treats a rare metabolic disorder, and Quinsair, approved for managing a chronic pulmonary infection in adult patients with cystic fibrosis.

Horizon Pharma Plc. will pay $9 in cash for each share of Novato, California-based Raptor Pharmaceutical Corp. and expects to close the deal in the fourth quarter.

Drugmakers in recent years have been shifting more money to developing rare disease treatments, as mass-market drugs lose patent protections.

More